Antipsychotic tapering
Antipsychotic tapering has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, May 1, 2026: “Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study”.
1 paper studies it2 findingsUpdated
See all 1 papers on antipsychotic tapering
At a glance
The findings reach people, from one lab or study. 1 lab in 2 countries.
“Compared with continuation after 12 weeks of treatment, estimated risks of delirium and fracture under the tapering strategy corresponded to 24-month ARDs of -2·46% (95% CI -4·10 to -1·27)”
None of its findings points the other way.
- 1 lab in 2 countries
- Funders: Monash University and 2 more
- 2 of 2 findings with company ties
- Humans1
What is antipsychotic tapering linked with?
2Studies link antipsychotic tapering with 2 measures, most often bone fracture (1 study) and delirium (1).
Bone fracture
downin humans1
1 study
Bone fracture
downin humans1
Antipsychotic tapering is linked with a lower risk of bone fracture in people living with dementia after 12 weeks of antipsychotic treatment (ARD -2.80% (95% CI -4.14 to -1.29)).
“and -2·80% (-4·14 to -1·29), respectively.”
Humansin people living with dementia after 12 weeks of antipsychotic treatment24 monthsn = 24,822
The lancet. Healthy longevity
Delirium
downin humans1
1 study
Delirium
downin humans1
Antipsychotic tapering is linked with a lower risk of delirium in people living with dementia after 12 weeks of antipsychotic treatment (ARD -2.46% (95% CI -4.10 to -1.27)).
“Compared with continuation after 12 weeks of treatment, estimated risks of delirium and fracture under the tapering strategy corresponded to 24-month ARDs of -2·46% (95% CI -4·10 to -1·27)”
Humansin people living with dementia after 12 weeks of antipsychotic treatment24 monthsn = 24,822
The lancet. Healthy longevity